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Introduction
Drug resistance is the major obstacle in management of cancer using chemotherapy.
Multidrug resistance (MDR) is a term used to describe the ability of cancer cells to develop resistance to a broad range of structurally and functionally unrelated chemotherapeutic agents. It is estimated that approximately 500,000 new cases of cancer each year will soon eventually exhibit multidrug resistant phenotype (1) . MDR is a complex phenomenon that can result from numerous mechanisms, including overexpressed ATP-dependent efflux pumps, which can diminish intracellular drug concentrations (such as P-glycoprotein (PGP) and multidrug-resistance-associated protein (MRP)), altered activity of specific enzyme systems which can diminish the chemosensitivity of the drug resistant cells (such as glutathione-S-transferase and topoisomerase), altered apoptosis regulation via loss of genes (such as p53) demanded for cell death or overexpression of genes (such as bcl-2) that block cell death, reduced drug uptake via alteration of folate carriers, increased DNA repair capacity and others (2) (3) (4) . Among these mechanisms, alteration of cell membrane transport (mediated by PGP) is the best studied phenomenon clinically (1) Among others, mesoporous silica nanoparticles (MSNs) possess several advantages for use as efficient DDS. MSNs have large surface areas and porous interiors that enable large doses of drugs. In addition, the silica framework lets MSNs resist hydrolysis and enzymatic degradation. Additionally the MSN's nanochannels we have used for this study provide a physical barrier to enzyme entry because most enzymes are bigger than the MSN's pores (~5 nm). The drugs are also conjugated in the inner walls of the MSN's nanochannels, which protects the drugs from in vivo hydrolysis and premature release. The advantage of MSNs is that they can enhance the oral bioavailability of drugs by reducing the "first pass effect". The "first pass effect" involves the liver metabolizing these drugs before they move into systemic circulation.
The reason for this is the liver has a high concentration of metabolizing enzymes (9) .
Moreover, cell uptake of MSNs can be increased through easily modified surface charge of MSNs (10, 11) .
Recently, MSNs have been used in numerous biological fields, such as fluorescent markers in vitro and in vivo, clinical diagnoses, drug and gene delivery, and MRI contrast agents (12) . In previously reported work, we developed the tri-functionalized MSNs for use as theranostic compounds that orchestrate the triad of imaging, target, and therapy in a single particle. The MSNs are functionalized in sequence with (A) a near-infrared (NIR) fluorescent contrast agent that is incorporated into the silica framework of MSNs for traceable imaging of particle targeting, (B) drug payloads in the MSN's nanochannels for therapeutic intervention and, (C) biomolecular ligands tiling the outermost surfaces of MSNs for highly-targeted particle delivery (13) .
We reported in our earlier study the use of positive-charge functionalized MSNs for controllable release of anionic drug molecules and to develop a pH-triggered drug release system. The MSN-TA can hold the drug molecules in acidic condition and protect them from degradation in the stomach. Therefore this nanoparticle could also be applied to oral drug delivery systems (14) . In addition, we also used MSNs with a covalently incorporated photosensitizer (PdTPP) for cancer photodynamic therapy (16) . It is known that high molecular weight (HMW) PEI has high cytotoxicity but is effective at transfecting nucleotides. Thus, selection of the appropriate PEI polymer size and dose of treatment is important to prevent particle toxicity.
However, our MSNs possess large pore diameters (~5.0 nm) and well-ordered pore structures. Although enzymes cannot easily enter MSN nanochanels, the protons found within acidic endosomes and lysosomes can; thereby providing a means of cleaving the labile hydrazone bonds that link drugs to the nanochannel walls. Thus we could conjugate doxorubicin with a pH sensitive linker (hydrazone bonds) and design sustained and proportionate release of doxorubicin. We could also increase cellular uptake of the drug through easily modified surface charges (17) .
In this study, we used MSN-Hydrazone-Dox nanoparticles, where the doxorubicin 
In Vitro Cytotoxicity
The MES-SA/Dx5 cells (1.5 × 10 4 cells/well) were treated with 5, 0.55 μg/ml free Dox and 50 μg/ml MSN-Hydrazone-Dox (containing doxorubicin equivalent dose at 0.55 µg/ml), for 24 h. The concentration of each drug was treated in triplicate.
Cytotoxicity was determined by MTT assay, in which 10 μl of MTT (5 mg/ml) solution was added to each well, and incubated for an additional 4 h, prior to the addition of 100 μl of color development solution. Absorbance was read on an ELISA plate reader with a test wavelength of 570 nm and a reference wavelength of 630 nm.
DNA Fragmentation

× 10
6 MES-SA/Dx5 cells were seeded onto 10 cm dish and incubated overnight in 5% CO 2 , at 37 °C. The cells were treated with 0.55 μg/ml free Dox and 50 μg/ml MSN-Hydrazone-Dox (containing doxorubicin equivalent dose at 0.55 µg/ml), for 24
and 48 h, at 37 °C. Cells were collected and resuspended in 200 μl PBS. The procedures followed the commercial genomic DNA extraction system from VIOGENE, wherein 1 μg DNA of each sample was loaded into 1% agarose gel and electrophoresis was performed at 50V, in a TBE buffer (90 mM Tris/HCl, 90 mM boric acid, 2 mM EDTA, pH 8.0), using 1kb DNA ladder molecular weight markers (Fermentas). The DNA was stained with 1.5 μg/ml ethidium bromide in TBE buffer and visualized under ultraviolet transillumination.
The TUNEL assay
Terminal deoxynucleotidyl transferase dUTP Nick End labeling (TUNEL) assay was used for the detection of apoptosis. Apoptotic cell death was detected using an in 
TEM Imaging of tumor tissue
For electron microscopy, tumor tissue specimens were fixed overnight in glutaraldehyde, buffered (2.5%) with PBS. The tissue was washed with 3 changes of PBS, and postfixed for 1 h in a solution containing OsO4 buffered (2%) with PBS, whereupon it was washed in 3 changes of dH 2 O and dehydrated stepwise in ethanol.
The tissue was polymerized using Spurr resin at 68 °C, for 15 h. The embedded specimens were thin sectioned at 70 nm and viewed on a Hitachi H-7650 TEM operating at 80 kV.
Immunohistochemistry
The apoptotic effects of MSN-Hydrazone-Dox were determined by active which was nearly the same as the control cells (indicated by gray filled histograms); with P-gp inhibitor, the cellular retention of doxorubicin gradually decreased; and the cellular retention of doxorubicin was 27.1%, at 24 h. The result showed that the uptake of doxorubicin in MSN-Hydrazone-Dox group was greater than in the free doxorubicin group and 77 times as much doxorubicin was retained in the cells compared with the free doxorubicin group at 24 h.
Results
MSN
MSN-Hydrazone-Dox is uptaken by the MES-SA/Dx5 cancer cell through endocytosis.
To verify that MSN-Hydrazone-Dox had been able to enter the MES-SA/Dx5 cancer cells through endocytosis and accumulate within the endosomes and lysosomes, we used confocal microscopy to characterize cellular uptake of Atto-647-labeled MSN-Hydrazone-Dox (Fig. 3) . In the treatment of Atto-647-MSN-Hydrazone-Dox to MES-SA/Dx5 cancer cells, endosomes and lysosomes were labeled with green fluorescent Lysotracker (Fig. 3B) . After 2 h of incubation, the red fluorescence of Atto-647-MSN-Hydrazone-Dox could be observed within MES-SA/Dx5 cancer cells (red in Fig. 3A) , and co-localized with Lysotracker green fluorescence (green in Fig. 3B , yellow in Fig. 3C ), indicating that the Atto-647-MSN-Hydrazone-Dox had become highly concentrated within the MES-SA/Dx5 the endosomes and lysosomes of the cancer cells. doxorubicin, when containing equivalent doses of doxorubicin. However, MSN-Hydrazone itself did not induce cell apoptosis. Thus, the in vitro performance of our MSN platform was more efficient than using the free drug alone. We employed TUNEL assays to detect breaks in the DNA strands (Fig. 5B) . By labeling the terminal ends of nucleic acids, TUNEL assays enable highly efficient detection of 
MSN-Hydrazone-Dox enhances cytotoxicity of the MES-
of 50 μg/mL MSN-Hydrazone-Dox, active caspase-3-positive tumor cells (brown in cytoplasm; Fig. 6B-a) were detected. However, they were not in free doxorubicin (same doxorubicin dose, 0.55 μg/ml), MSN-Hydrazone, or control (Fig. 6B-b, c, d ). In present study, 100 μM VRP slightly increased intracellular accumulation of doxorubicin ( Fig. 2A) . However VRP enhanced cytotoxicity in normal cells only at high concentration (25) . The MSN-Hydrazone-Dox nanoparticle on the other hand improved cell uptake and intracellular doxorubicin retention without PGP inhibitor in MES-SA/Dx5 cancer cells (Fig. 2B) . . S2C ). The MES-SA/Dx5 cells were treated with additional P-gp inhibitor (100 μM Verapamil); the red fluorescence of free doxorubicin was higher than the absence of P-gp inhibitors within MES-SA/Dx5 cancer cells (red in Fig. S2B and D) . 
Discussion
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